Lorlatinib

Active Ingredient: Lorlatinib
Form: Capsule
Brand Name: Lorbrena
Generic Name: Lornatib
Generic Manufacturer: Ziska Pharmaceuticals

Indications:
Lorbrena is indicated for the treatment of adults with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed after treatment with other ALK inhibitors such as Alectinib, Ceritinib, or Crizotinib.

Dosage and Administration:
The recommended dose is 100 mg orally once daily. If not tolerated, the dose may be reduced to 75 mg, then to 50 mg daily if necessary. If a dose is missed, follow your physician's instructions—do not double up doses.

Common Side Effects:
Elevated cholesterol and triglycerides, edema, peripheral neuropathy, cognitive and mood changes, fatigue, and weight gain.

Storage:
Store below 30°C in a dry place, away from moisture and light. Keep out of reach of children.

Frequently Asked Questions

Q: What is the relationship between Lorbrena and Lorlatinib?
A: Lorbrena is the brand name registered by the original manufacturer. Lorlatinib is its active ingredient.

Q: Is the Lorbrena sold by Mediva Rx the original brand-name drug?
A: No. Mediva Rx offers a high-quality generic version manufactured by one of Bangladesh’s top 10 pharmaceutical companies. It contains the same active ingredient and therapeutic efficacy as the original, and is tested and approved by the Directorate General of Drug Administration (DGDA).

Q: Is the manufacturer of this generic version reliable?
A: Yes. We work with Ziska Pharmaceuticals, one of Bangladesh’s leading pharmaceutical manufacturers. They have in-house R&D, production, and quality control labs, and are internationally certified for Good Manufacturing Practice (GMP). You can purchase with confidence.

Disclaimer:
This information is for reference only. Please consult your physician and refer to the official medication guide and the latest clinical research when making treatment decisions.

Drug Instructions (Package Insert):
Download Link